Loading...

NUWE NUWELLIS INC US FDA Inspections 8-K Filing

NWLL

NW

NUWELLIS INC

(NUWE)

2023 8-K

Show Summary

Summary

Financial Results Report

Voluntary Delisting

Delisting due to Non-Compli...

Equity Offerings

Reverse Stock Split

Financial Statements

Corporate Presentation

Financial Results

Nasdaq Compliance

Financial Results

Warrant Inducement

Financial Results

Settlement Agreement

Agreement Termination

Financial Results

Nasdaq Compliance

Agreement for Registered Di...

Amendment and Risk Factor U...

Corporate Presentation and ...

Termination of Agreement

Reverse Stock Split

Delisting Notice

Amendment to Supply Agreement

Earnings Report

Public Offering

Financial Results

Corporate Presentation

Financial Results Announcement

Appointment and Resignation

Placement Agency Agreement ...

FDA Approval for Selective ...

Appointment of CFO

Resignation of CFO and Appo...

Financial Results

Supply and Collaboration Ag...

Appointment of Michael McCo...

Annual Meeting Results

Financial Results

Presentation at Oppenheimer...

Financial Results and Induc...

Management Changes

Financial Results

Meeting Adjournment and Vot...

External Links:

Nuwellis, Inc. announced that its distribution partner, SeaStar Medical Holding Corporation, received correspondence from the FDA indicating that SeaStar's Selective Cytopheretic Device Pediatric is approvable for use in children with acute kidney injury and sepsis.

AI Assistant

NUWELLIS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.